DE60011446D1 - Substituierte pyridino pentaazamakrozykle komplexe mit superoxid-dismutase-aktivität - Google Patents

Substituierte pyridino pentaazamakrozykle komplexe mit superoxid-dismutase-aktivität

Info

Publication number
DE60011446D1
DE60011446D1 DE60011446T DE60011446T DE60011446D1 DE 60011446 D1 DE60011446 D1 DE 60011446D1 DE 60011446 T DE60011446 T DE 60011446T DE 60011446 T DE60011446 T DE 60011446T DE 60011446 D1 DE60011446 D1 DE 60011446D1
Authority
DE
Germany
Prior art keywords
superoxide dismutase
dismutase activity
pentaaza macrocycle
substituted pyridino
macrocycle complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60011446T
Other languages
English (en)
Other versions
DE60011446T2 (de
Inventor
Dennis Riley
William L Neumann
Susan L Henke
Patrick Lennon
Karl W Aston
Daniela Salvemini
James A Sikorski
Yvette Fobian
Margaret L Grapperhaus
Carrie L Kusturin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monsanto Co
Original Assignee
Monsanto Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monsanto Co filed Critical Monsanto Co
Application granted granted Critical
Publication of DE60011446D1 publication Critical patent/DE60011446D1/de
Publication of DE60011446T2 publication Critical patent/DE60011446T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60011446T 1999-09-16 2000-09-14 Substituierte Pyridinopentaazamakrocyclokomplexe mit Superoxiddismutaseaktivität Expired - Lifetime DE60011446T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/398,120 US6214817B1 (en) 1997-06-20 1999-09-16 Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US398120 1999-09-16
PCT/US2000/025154 WO2001019823A2 (en) 1999-09-16 2000-09-14 Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity

Publications (2)

Publication Number Publication Date
DE60011446D1 true DE60011446D1 (de) 2004-07-15
DE60011446T2 DE60011446T2 (de) 2005-07-07

Family

ID=23574065

Family Applications (3)

Application Number Title Priority Date Filing Date
DE60035440T Expired - Lifetime DE60035440T2 (de) 1999-09-16 2000-09-14 Verwendung von substituierten Pyridinopentaazamakrozyklen-Komplexen mit Superoxiddismutaseaktivität
DE60011446T Expired - Lifetime DE60011446T2 (de) 1999-09-16 2000-09-14 Substituierte Pyridinopentaazamakrocyclokomplexe mit Superoxiddismutaseaktivität
DE60035724T Expired - Lifetime DE60035724T2 (de) 1999-09-16 2000-09-14 Substituierte Pyridino pentaazamakrozyklische Liganden

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60035440T Expired - Lifetime DE60035440T2 (de) 1999-09-16 2000-09-14 Verwendung von substituierten Pyridinopentaazamakrozyklen-Komplexen mit Superoxiddismutaseaktivität

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60035724T Expired - Lifetime DE60035724T2 (de) 1999-09-16 2000-09-14 Substituierte Pyridino pentaazamakrozyklische Liganden

Country Status (12)

Country Link
US (1) US6214817B1 (de)
EP (3) EP1420022B1 (de)
JP (2) JP2003509423A (de)
AT (3) ATE368039T1 (de)
AU (1) AU784078B2 (de)
CA (1) CA2382105C (de)
DE (3) DE60035440T2 (de)
DK (1) DK1212323T3 (de)
ES (3) ES2293106T3 (de)
HK (1) HK1046689B (de)
PT (1) PT1212323E (de)
WO (1) WO2001019823A2 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
CA2229781A1 (en) * 1995-08-17 1997-02-27 Monsanto Company Methods of diagnostic image analysis using bioconjugates of metal complexes of nitrogen-containing macrocyclic ligands
US20050171198A1 (en) * 1997-06-20 2005-08-04 Metaphore Pharmaceuticals, Inc. SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease
ATE238307T1 (de) 1997-11-03 2003-05-15 Univ Duke Substituierte porphyrinen
CA2359116C (en) * 1999-01-25 2009-03-17 National Jewish Medical And Research Center Substituted porphyrins
US20030069281A1 (en) * 2000-06-14 2003-04-10 Irwin Fridovich Tetrapyrroles
US20020072512A1 (en) * 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
EP1347773B1 (de) * 2001-01-05 2010-04-14 Metaphore Pharmaceuticals Inc. Zusammensetzungen und verfahren zur erhöhung der zytokin-aktivität und zur behandlung der hypotension assoziiert mit der verabreichung von zytokinen
US20030050297A1 (en) 2001-01-19 2003-03-13 Crapo James D. Cancer therapy
EP1353655A2 (de) * 2001-01-26 2003-10-22 Metaphore Pharmaceuticals Inc. Verfahren zur behandlung von neurodegenerativen erkrankungen mit pentaaza-makrozyklischen ligandkomplexen
US20040137638A1 (en) 2002-03-04 2004-07-15 Slomczynska Urszula J. Chromatography of metal complexes
RU2003129271A (ru) * 2001-03-02 2005-03-20 Метафор Фармасьютикалз, Инк. (Us) Хроматография комплексов металлов
CA2449024A1 (en) * 2001-06-01 2002-12-12 National Jewish Medical And Research Center Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
EP1417219A4 (de) * 2001-06-08 2005-05-25 Metaphore Pharmaceuticals Inc Bibliotheken konformationsgehinderter peptide, chirale azakronen und peptidomimetika, und verfahren zu deren herstellung
WO2003000696A1 (en) * 2001-06-26 2003-01-03 Metaphore Pharmaceuticals, Inc. COMBINATION THERAPY OF AN SODm AND A CORTICOSTEROID FOR PREVENTION AND/OR TREATMENT OF INFLAMMATORY DISEASE
US20040132706A1 (en) * 2001-10-05 2004-07-08 Daniela Salvemini Composition comprising a catalyst for the dismutation of superoxide and use of the composition for preventing and treating hypotension
PL210225B1 (pl) * 2001-12-14 2011-12-30 Alcon Zastosowanie związku naśladującego dysmutazę ponadtlenkową jako środka do leczenia zaburzeń i chorób oczu
CA2488500A1 (en) * 2002-06-07 2003-12-18 Duke University Substituted porphyrins
US6835387B2 (en) 2002-06-11 2004-12-28 Scimed Life Systems, Inc. Sustained release of superoxide dismutase mimics from implantable or insertable medical devices
US20030232784A1 (en) * 2002-06-14 2003-12-18 Benedict James J. Hyaluronic acid-associated superoxide dismutase mimics and their use in the treatment of joint pain
CA2397684A1 (en) * 2002-08-12 2004-02-12 Michael P. Murphy Mitochondrially targeted antioxidants
AU2003286389A1 (en) * 2002-11-29 2004-06-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ace-inhibitors having antioxidant and nitricoxid-donor activity
MXPA05005937A (es) * 2002-12-06 2005-08-18 Alcon Inc Imitaciones de superoxido de dismutasa para el tratamiento de trastornos y enfermedades oculares.
CN1717234A (zh) * 2002-12-06 2006-01-04 爱尔康公司 用于治疗眼紊乱和疾病的超氧化物岐化酶模拟物
US7299082B2 (en) 2003-10-31 2007-11-20 Abbott Diabetes Care, Inc. Method of calibrating an analyte-measurement device, and associated methods, devices and systems
JP2007513948A (ja) 2003-12-11 2007-05-31 アルコン，インコーポレイテッド 視神経損傷および網膜損傷の処置のためのスーパーオキシドジスムターゼ模倣物
FR2863892B1 (fr) * 2003-12-18 2007-05-11 Univ Paris Descartes Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
US8165651B2 (en) * 2004-02-09 2012-04-24 Abbott Diabetes Care Inc. Analyte sensor, and associated system and method employing a catalytic agent
US7699964B2 (en) 2004-02-09 2010-04-20 Abbott Diabetes Care Inc. Membrane suitable for use in an analyte sensor, analyte sensor, and associated method
US20120301403A1 (en) 2007-06-21 2012-11-29 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
US8217166B2 (en) * 2005-05-05 2012-07-10 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
KR100724586B1 (ko) 2005-12-09 2007-06-04 세종대학교산학협력단 수퍼옥사이드 디스뮤타아제 활성을 갖는 고리화합물
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
PT2056675T (pt) 2006-10-12 2019-05-09 Galera Labs Llc Métodos de tratamento da mucosite oral
WO2008114017A2 (en) * 2007-03-19 2008-09-25 Imperial Innovations Limited Compositions and methods relating to influenza infection
EP2859916B1 (de) 2008-05-22 2017-11-29 Galera Labs, LLC Antimitotika mit Superoxid Dismutase Mimetika für die Kombinationstherapie gegen Krebs
ES2600469T3 (es) 2008-05-23 2017-02-09 National Jewish Health Un compuesto para su uso en el tratamiento de lesiones asociadas con la exposición al gas fosgeno o al gas de cloro
CN102164987B (zh) 2008-08-22 2015-07-08 诺沃梅尔公司 用于合成聚合物的催化剂和方法
CA2746768A1 (en) * 2008-12-17 2010-07-08 Altheus Therapeutics, Inc. Enema formulations
AU2012316397B2 (en) * 2011-09-26 2016-07-21 Galera Labs, Llc Methods for treatment of diseases
EP2797597B1 (de) 2011-12-28 2020-02-26 Global Blood Therapeutics, Inc. Substituierte heteroarylaldehydverbindungen und verfahren zu deren verwendung bei der erhöhung einer gewebeoxigenierung
LT3141542T (lt) 2011-12-28 2020-09-25 Global Blood Therapeutics, Inc. Pakeistieji benzaldehido junginiai ir jų panaudojimas didinant audinių aprūpinimą deguonimi
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
PE20160078A1 (es) 2013-03-15 2016-03-02 Global Blood Therapeutics Inc Compuestos y sus usos para modular la hemoglobina
SG10201802911RA (en) 2013-03-15 2018-05-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
SG11201507349TA (en) 2013-03-15 2015-10-29 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
AU2014374361B9 (en) 2013-12-31 2019-07-04 Abbott Diabetes Care Inc. Self-powered analyte sensor and devices using the same
SG10201804139VA (en) 2014-02-07 2018-06-28 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
MX2018001605A (es) * 2015-08-11 2018-09-26 Galera Labs Llc Complejos de anillos macrocíclicos de pentaaza que poseen biodisponibilidad oral.
MX2018006832A (es) 2015-12-04 2018-11-09 Global Blood Therapeutics Inc Regimenes de dosificacion de 2-hidroxi-6-((2-(1-isopropil-1h-piraz ol-5-il)-piridin-3-il)-metoxi)-benzaldehido.
TWI825524B (zh) 2016-05-12 2023-12-11 美商全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
WO2018045348A2 (en) * 2016-09-01 2018-03-08 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
WO2018152353A2 (en) 2017-02-15 2018-08-23 Galera Labs, Llc Pentaaza macrocyclic ring complexes for local intestinal delivery
KR20190141690A (ko) * 2017-04-13 2019-12-24 갈레라 랩스, 엘엘씨 펜타아자 마크로시클릭 고리 복합체를 사용한 조합 암 면역요법
EA201992431A1 (ru) 2017-10-13 2020-03-13 ГАЛЕРА ЛЭБЗ, ЭлЭлСи Комбинированная иммунотерапия рака с использованием пента-аза-макроциклического кольцевого комплекса
CN111902147A (zh) 2018-01-31 2020-11-06 加莱拉实验室有限责任公司 五氮杂大环状环配合物和基于铂的抗癌剂的组合癌症治疗
ES2966707T3 (es) 2018-10-01 2024-04-23 Global Blood Therapeutics Inc Moduladores de la hemoglobina para el tratamiento de la drepanocitosis
CN115260178A (zh) * 2022-08-09 2022-11-01 上海师范大学 一种吡啶骨架ncn噁唑啉类配体的合成方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001212A (en) 1973-10-03 1977-01-04 E. I. Du Pont De Nemours And Company Macrocyclic polyamines
US3930867A (en) 1974-01-07 1976-01-06 E. I. Du Pont De Nemours And Company Macrocyclic polyamines as sensitizers for silver halide emulsions
NO149961C (no) 1981-06-01 1984-07-25 Borregaard Ind Fremgangsmaate for fremstilling av n-(2-hydroksyetyl)-derivater av makrocykliske polyaminer, inneholdende flere nitrogenatomer i 1,4-forhold i ringen
JPS61226751A (ja) 1985-03-30 1986-10-08 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料用処理液及びその処理方法
US4968616A (en) 1986-05-16 1990-11-06 Masayasu Inoue Superoxide dismutase derivatives, method of producing same and medicinal use of same
US5096724A (en) 1988-06-03 1992-03-17 Aquanautics Corporation Methods, compositions, and systems for ligand extraction
US5252720A (en) 1989-03-06 1993-10-12 Board Of Regents, The University Of Texas System Metal complexes of water soluble texaphyrins
GB9001245D0 (en) 1990-01-19 1990-03-21 Salutar Inc Compounds
WO1991010669A1 (en) 1990-01-19 1991-07-25 Cockbain, Julian, Roderick, Michaelson Chelating compounds
GB9024208D0 (en) 1990-11-07 1990-12-19 Salutar Inc Compounds
CA2072934C (en) 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
ES2113952T3 (es) 1991-07-19 1998-05-16 Monsanto Co Complejos de manganeso con ligandos macrociclicos nitrogenados eficaces como catalizadores para dismutar superoxidos.
EP0579802B1 (de) 1991-12-10 2000-04-26 The Dow Chemical Company Bicylclische, polyazamakrocyclocarbonsäure-komplexe, konjugate, herstellung und verwendung als kontraststoffe
US5834509A (en) 1992-12-07 1998-11-10 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5696109A (en) 1992-12-07 1997-12-09 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5403834A (en) 1992-12-07 1995-04-04 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US6204259B1 (en) 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
HUT76318A (en) 1994-04-22 1997-08-28 Searle & Co Diagnostic image analysis with metal complexes
AU6031096A (en) 1995-06-05 1996-12-24 Duke University Nitrosylated and nitrated superoxide oxidants and reductants
US6525041B1 (en) 1995-06-06 2003-02-25 Pharmacia Corporation Manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
JPH11507621A (ja) 1995-06-07 1999-07-06 モンサント カンパニー 置換ポリアザ大環状化合物の製造法
SE509595C2 (sv) * 1996-01-25 1999-02-15 Sandvik Ab Skär för spånavskiljande metallbearbetning
WO1997033877A1 (en) * 1996-03-13 1997-09-18 Monsanto Company Bioconjugates of manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US6180620B1 (en) 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals

Also Published As

Publication number Publication date
ATE368039T1 (de) 2007-08-15
DE60011446T2 (de) 2005-07-07
HK1046689B (zh) 2005-03-11
EP1212323A2 (de) 2002-06-12
DE60035724D1 (de) 2007-09-06
DE60035724T2 (de) 2008-04-30
WO2001019823A9 (en) 2002-09-26
HK1046689A1 (en) 2003-01-24
JP2003509423A (ja) 2003-03-11
PT1212323E (pt) 2004-10-29
WO2001019823A2 (en) 2001-03-22
AU784078B2 (en) 2006-02-02
DE60035440T2 (de) 2008-03-13
DE60035440D1 (de) 2007-08-16
JP2012097097A (ja) 2012-05-24
EP1420019A1 (de) 2004-05-19
ATE268774T1 (de) 2004-06-15
CA2382105A1 (en) 2001-03-22
ES2222925T3 (es) 2005-02-16
WO2001019823A3 (en) 2001-09-07
EP1212323B1 (de) 2004-06-09
AU7702400A (en) 2001-04-17
EP1420022B1 (de) 2007-07-04
ATE366254T1 (de) 2007-07-15
CA2382105C (en) 2012-01-10
DK1212323T3 (da) 2004-10-25
ES2291759T3 (es) 2008-03-01
EP1420022A1 (de) 2004-05-19
ES2293106T3 (es) 2008-03-16
US6214817B1 (en) 2001-04-10
EP1420019B1 (de) 2007-07-25

Similar Documents

Publication Publication Date Title
DE60011446D1 (de) Substituierte pyridino pentaazamakrozykle komplexe mit superoxid-dismutase-aktivität
ATE511222T1 (de) Komplex der formel l2irx
PL356486A1 (en) Catalysts for hydrosilylation reactions
AU6023796A (en) Manganese or iron complexes of nitrogen-containing macrocycl ic ligands effective as catalysts for dismutating superoxide
EA200500607A1 (ru) Рутениевые комплексы в качестве (пред)катализаторов для реакций метатезиса
EP0679155A1 (de) Mangan-komplexe von stickstoff-enthaltenden macrozyklischen liganden und ihre verwendung als superoxiddismutase katalysatoren.
DE69730820D1 (de) Polyazomacrocyclofluoromonoalkylphosphensäure, ihre komplexe zur verwendung als kontrastmittel
ATE227297T1 (de) 2-pyridylmethylen-polyazamacrocyclophosphonsäur n,ihre komplexe und derivate zur verwendung als kontrastmittel
WO2001014376A8 (en) Novel spiro compounds
ATE283867T1 (de) Kontrolle des molekulargewichts in der olefinpolymerisation
DE69927688D1 (de) Antivirales Mittel in Kombination mit Strahlentherapie zur Verwendung in der Behandlung von Krebs
EP1304121A4 (de) Inhibitoren der koerpergewichtszunahme
EP0522841A3 (de) Zersetzung von organischen Hydroperoxiden
BR0315869A (pt) Uso de compostos de complexos de metais como catalisadores de oxidação
AU2003240732A1 (en) Use of transition metal complexes with nitrogen-containing polydentate ligands as a bleaching catalyst and bleaching agent composition
IL125889A0 (en) Bioconjugates of manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
WO2002058686A3 (en) Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
NO984165D0 (no) Jernkomplekser av nitrogen-inneholdende makrocykliske ligander effektive som katalysatorer for dismuterende superoksider
DE69912193D1 (de) Substituierte 2-Hydroxybenzophenone, ihre Herstellung, ihre Verwendung als fungizide und ihre fungizide Zusammensetzungen
PT1467812E (pt) Sais de complexo de manganês (iv) e sua utilização como catalisadores de oxidação
BR0305065A (pt) Uso de complexos de metais de transição com ligantes polidentados que contem nitrogênio como um catalisador de alvejamento e composição de agente alvejante
NO982240D0 (no) FremgangsmÕte ved oksidering av organiske substrater i nµrvµr av metallkomplekser av tetra-, penta-, og heksakooridinerte ligander, samt oksidasjonskatalysatorer inneholdende disse
ES2159087T3 (es) Oxindoles sustituidos con adamantilo como agentes farmaceuticos.
ATE141918T1 (de) Isoquinolinderivate
RU93019809A (ru) Тетрофтортетраазапорфин

Legal Events

Date Code Title Description
8364 No opposition during term of opposition